NCT05270200View on ClinicalTrials.gov

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

Azacitidine

Patients will recieve six courses of azacitidine 50mg/m2 through a needle under skin on Days 1-3.Each course is 28 days long.

DRUG

Chidamide

Patients will recieve oral chidamide 5mg per day for no more than 2 years.

Trial Locations (1)

510250

RECRUITING

Nanfang Hospital of Southern Medical University, Guanzhou

All Listed Sponsors
lead

Zhujiang Hospital

OTHER